Cidara Therapeutics, Inc. (Nasdaq:CDTX), announced the initiation of a Phase 1, randomized, double-blind, dose-escalation study to determine the safety, tolerability, and pharmacokinetics of CD101 IV in healthy subjects. The advancement of our first product candidate into the clinic ahead of schedule is a significant next step toward our mission to address the urgent need for effective new antifungal treatments,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “CD101 IV is a novel, long-acting antifungal that could ultimately provide physicians with a new treatment option for their patients fighting serious, life-threatening fungal infections. Cidara Therapeutics, Inc. (NASDAQ:CDTX) belongs to Healthcare sector. Its weekly performance is 2.44%. On last trading day company shares ended up $14.30. Cidara Therapeutics, Inc. (NASDAQ:CDTX) distance from 50-day simple moving average (SMA50) is -5.01%.
Advaxis, Inc. (ADXS), announced that the company’s scientific founder, Yvonne Paterson, Ph.D., Professor of Microbiology at the Perelman School of Medicine at the University of Pennsylvania, will give a presentation titled “HER-2/neu as a target for Listeria-based cancer immunotherapy for breast cancer” on Tuesday, August 4 at 9:00 a.m. BST, at the 2015 World Congress on Breast Cancer in Birmingham, UK. Advaxis, Inc. (NASDAQ:ADXS) shares moved down -3.15% in last trading session and ended the day at $15.35. Its return on assets is -88.10%. Advaxis, Inc. (NASDAQ:ADXS) quarterly performance is -13.08%.
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced that it plans to release its financial results for the quarter and three months ended June 30, 2015, after the close of market on Thursday, August 6, 2015.Consistent with the Company’s policy, Taro will conduct its next earnings call when it announces its financial results for the six months ending September 30, 2015.On 04 August, Taro Pharmaceutical Industries Ltd. (NYSE:TARO) shares moved down -0.45% and was closed at $139.97. TARO EPS growth in last 5 year was 49.00%. Taro Pharmaceutical Industries Ltd. (NYSE:TARO) year to date (YTD) performance is -5.55%.
Now, it seems that Twitter Inc (NYSE:TWTR) is working on what could become a response to this threat. The company has confirmed that it is rolling out a new experimental feature to users of its iOS and Android apps: A “News” tab that highlights news stories from a number of mainstream media partners, including the New York Times and USA Today. On 04 August, Twitter Inc (NYSE:TWTR) shares advanced 0.24% and was closed at $29.34. TWTR EPS growth in last 5 year was 0.00%. Twitter Inc (NYSE:TWTR) year to date (YTD) performance is -18.20%.
Star Bulk Carriers Corp. (NASDAQ:SBLK) will begin trading ex-dividend on July 29, 2015. A cash dividend payment of $0.5 per share is scheduled to be paid on August 15, 2015. Shareholders who purchased SBLKL prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 3rd quarter that SBLKL has paid the same dividend. Star Bulk Carriers Corp. (NASDAQ:SBLK) shares moved up 1.29% in last trading session and ended the day at $3.13. SBLK Gross Margin is 31.60% and its return on assets is -1.00%. Star Bulk Carriers Corp. (NASDAQ:SBLK) quarterly performance is -17.20%.